Literature DB >> 20193369

[Optimization of extracting method and inhibitory action of recombinant human endostatin in bladder cancer].

Ming-hua Ren1, Shao-bin Ni, Qi-yin Chen, Wan-hai Xu, Chang-lin Wang, Yi-ming Fu, Zhi-xing Jiao, Li Ma, Zhong-shan Zhao, Xing-han Liu.   

Abstract

OBJECTIVE: To explore the optimal method for protein expression in rhES (recombinant human endostatin) and study the anti-tumor activities of rhES in solid tumor and established cell line.
METHODS: Different IPTG concentrations, the timing of adding IPTG into the culture medium and the different time of expression were employed to explore the optimized conditions of protein expression. Activity examination: (1) animal experiment: nude mice bearing subcutaneous cancer in treated group and controlled group were observed. (2) cellular experiment: the inhibitory effect of rhES in T-24 established cell line were observed by MTT assay and cancer cell growth curve.
RESULTS: The expression of rhES protein was 58.65%. Of all the E. coli body proteins, the protein purity after purification was 96.22%. Activity examination indicated that rhES could inhibit the growth of solid tumor and the established cell line. In animal experiment, the tumor inhibition rate was 66.8%. Cell experiment: the 50% inhibitory concentration (IC(50)) was 22 microg/ml. The cell population decreased 58.75% than the control group at Day 7 in the tumor cell growth curve.
CONCLUSION: A high expression and activity of rhES protein can be obtained by the optimized expression conditions. rhES can inhibit the cellular growth in both solid tumor and established cell line of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20193369

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  The inhibition of Endostar on the angiogenesis and growth of gastrointestinal stromal tumor xenograft.

Authors:  Tian-bao Wang; Xiu-qing Wei; Wei-hao Lin; Han-ping Shi; Wen-guang Dong
Journal:  Clin Exp Med       Date:  2011-06-10       Impact factor: 3.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.